Announced Thu, 23 Jul · 17:54 IST
Beta Drugs submits revised Q1 results after UDIN omission flagged by NSE
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.4%1-day move
₹2282.50
prior close
₹2258.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+0.7+0.6+0.7-2.4—————————
Up moveDown movePending
AI summary
Beta Drugs has filed revised Q1 FY27 results (quarter ended June 2026) with NSE after the exchange flagged a missing UDIN on the original 20 July 2026 filing. The company called it an inadvertent oversight. Consolidated revenue rose to about Rs 127.13 crore from Rs 103.19 crore year on year, and net profit climbed to about Rs 15.80 crore from Rs 11.60 crore. Standalone revenue fell to Rs 57.69 crore from Rs 69.30 crore.
Likely market impact
Procedural correction, not a financial restatement. Consolidated profit growth of about 36 percent year on year is reassuring for shareholders.